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Abstract
Multiple breast cancer loci have been identified in previous genome-wide association studies, but they were mainly con-
ducted in populations of European ancestry. Women of African ancestry are more likely to have young-onset and oestrogen
receptor (ER) negative breast cancer for reasons that are unknown and understudied. To identify genetic risk factors for breast
cancer in women of African descent, we conducted a meta-analysis of two genome-wide association studies of breast cancer;
one study consists of 1,657 cases and 2,029 controls genotyped with Illumina’s HumanOmni2.5 BeadChip and the other study
included 3,016 cases and 2,745 controls genotyped using Illumina Human1M-Duo BeadChip. The top 18,376 single nucleotide
polymorphisms (SNP) from the meta-analysis were replicated in the third study that consists of 1,984 African Americans
cases and 2,939 controls. We found that SNP rs13074711, 26.5 Kb upstream of TNFSF10 at 3q26.21, was significantly associated
with risk of oestrogen receptor (ER)-negative breast cancer (odds ratio [OR]¼1.29, 95% CI: 1.18-1.40; P¼1.810 8). Functional
annotations suggest that the TNFSF10 gene may be involved in breast cancer aetiology, but further functional experiments
are needed. In addition, we confirmed SNP rs10069690 was the best indicator for ER-negative breast cancer at 5p15.33
(OR¼1.30; P¼2.410 10) and identified rs12998806 as the best indicator for ER-positive breast cancer at 2q35 (OR¼1.34;
P¼2.210 8) for women of African ancestry. These findings demonstrated additional susceptibility alleles for breast cancer
can be revealed in diverse populations and have important public health implications in building race/ethnicity-specific risk
prediction model for breast cancer.
Introduction
As the most common cancer among women both in the United
States and in the world (1), breast cancer is a heterogeneous dis-
ease with several molecular subtypes defined by biomarkers
such as oestrogen receptor (ER). Oestrogen receptor-negative
breast cancer is more likely to be early-onset and is associated
with worse clinical outcomes. African Americans are more
likely to have ER-negative breast cancer, for reasons that remain
unknown and understudied (2). Indigenous Africans have an
even higher proportion of ER-negative breast cancer than
African Americans (3,4), suggesting that previously unrecog-
nized genetic factors play an important role in this racial differ-
ence. Multiple genome-wide association studies (GWAS) of
breast cancer have been conducted but mainly in populations of
European ancestry, which have revealed more than 90 common
susceptibility loci (5–21). However, only a few of these loci
appear to be specific for ER-negative disease (19,21). Because of
its aggressive nature, there is an unmet clinical need for predic-
tive genetic markers of susceptibility to ER-negative breast can-
cer, especially among women of African ancestry.
Results
The study consists of a discovery stage and a validation stage.
In the discovery stage, we conducted a meta-analysis of two
GWAS (Table 1). One study (GWAS of Breast Cancer in the
African Diaspora, ROOT consortium) consists of 1,657 cases and
2,029 controls, while the other study (African American Breast
Cancer Consortium, AABC) consists of 3,016 cases and 2,745
controls. Genotyping was conducted using the Illumina
HumanOmni2.5-8v1 and Illumina Human1M-Duo BeadChip in
ROOT and AABC studies, respectively. To combine genotyping
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results from the two studies, we imputed genotypes for single
nucleotide polymorphisms in the 1000 Genomes Project using
IMPUTE2 (22). Quantile-quantile plots of P-values showed little
inflation of test statistics in ROOT, AABC, or in the meta-
analysis (all genomic control inflation factor k’s< 1.04;
Supplementary Material, Fig. S1), indicating that there was no
residual cryptic population substructure in the analysis. Results
of the meta-analysis are summarized in the Manhattan plots
(Fig. 1). The top 20,000 SNPs from the meta-analysis of overall
breast cancer or ER-specific disease were considered for stage 2
replication genotyping in an independent sample of 1,984 inva-
sive cases and 2,939 controls assembled by the African
American Breast Cancer Epidemiology and Risk (AMBER) con-
sortium (Table 1). Of the 20,000 SNPs, 18,376 SNPs passed the
design stage for the Illumina custom chip and were successfully
genotyped.
In the combined analysis of GWAS discovery and validation
stages, associations of SNPs in three regions attained genome-
wide significance (Table 2), with one of these regions (3q26.21)
not identified in previous GWAS. All three SNPs were signifi-
cantly associated with overall risk of breast cancer, but the
strength of the association varied by breast cancer subtype. SNP
rs12998806 at 2q35 was associated with ER-positive breast can-
cer (G-allele, OR¼ 1.34; P¼ 2.2 10 8), but not with ER-negative
disease (OR¼ 0.99). SNP rs13074711 at 3q26.21 was significantly
associated with ER-negative breast cancer (T-allele, OR¼ 1.29;
P¼ 1.8 10  8), but only weakly with ER-positive breast cancer
(OR¼ 1.10, P¼ 0.0094). Similarly, rs10069690 at 5p15.33 was
associated with ER-negative breast cancer (T-allele, OR¼ 1.30;
P¼ 2.4 10  10), but only weakly associated with ER-positive dis-
ease (OR¼ 1.08, P¼ 0.03). SNP rs12998806 was imputed in ROOT
and AABC (imputation information score r2>0.99) and
rs13074711 was imputed in ROOT (r2¼0.987). We genotyped
these two SNPs in 96 samples from ROOT using sequencing
technique, and found that the genotyping results were 100%
and 99% in concordance with imputation for rs12998806 and
rs13074711, respectively, suggesting that the results based on
imputed SNPs were reliable.
The rs13074711 SNP is located 26.5 Kb upstream of the
Tumour Necrosis Factor Superfamily, Member 10 (TNFSF10)
gene and the association signal for ER-negative breast cancer
maps to a linkage disequilibrium (LD) block of 100 Kb between
172.2 Mb and 172.3 Mb on chromosome 3, which covers the
TNFSF10 gene (Fig. 2A, Supplementary Material, Fig S2). The
TNFSF10 gene, also known as TRAIL or APO2L, encodes a cyto-
kine that belongs to the tumour necrosis factor ligand family.
TNFSF10 cytokine preferentially induces apoptosis in tumour
cells or transformed cells, but is not toxic to normal cells (23).
The TNFSF10 gene is expressed in a wide range of tissues, in-
cluding blood lymphocytes, breast, prostate, lungs, minor sali-
vary grand and spleen (24). Interestingly, triple-negative breast
cancer cell lines have been shown to be very sensitive to
TNFSF10-induced apoptosis, while ER-positive cell lines were
resistant to TNFSF10-induced apoptosis (25). Because of its im-
portant role in tumour apoptosis, several TNFSF10 receptor ago-
nists or recombinant forms of TNFSF10 are in clinical
Table 1. Characteristics of study participants in the GWAS of breast cancer for women of African ancestry
No. of subjects Mean (SD) of age in years Oestrogen receptor (n, %)
Study Study Name Case Control Case Control Positive Negative
ROOT consortium
NBCS Nigerian Breast Cancer Study 711 624 48 (12) 45 (12) 99 (70) 42 (30)
BNCS Barbados National Cancer Study 92 229 57 (15) 55 (13)
RVGBC Racial Variability in Genotypic Determinants
of Breast Cancer Risk Study
145 257 46 (11) 41 (12) 25 (48) 27 (52)
CCPS Chicago Cancer Prone Study 394 387 47 (12) 45 (11) 140 (45) 171 (55)
BBCS Baltimore Breast Cancer Study 95 102 54 (14) 52 (13) 44 (49) 45 (51)
SCCS Southern Community Cohort Study 220 430 57 (9) 57 (9) 66 (36) 118 (64)
subtotal 1657 2029 49 (12) 48 (13) 374 (48) 403 (52)
AABC consortium
MEC Multiethnic Cohort Study 694 990 66 (9) 67 (9) 408 (70) 176 (30)
CARE Women’s Contraceptive and Reproductive
Experiences Study, Log Angeles component
357 215 49 (8) 48 (8) 183 (58) 130 (42)
WCHS Women’s Circle of Health Study 261 239 50 (10) 50 (9) 131 (62) 80 (38)
SFBCS San Francisco Bay Area Breast Cancer Study 165 220 56 (12) 55 (12) 84 (63) 50 (37)
NC-BCFR Northern California site of the Breast Cancer
Family Registry
424 50 50 (9) 49 (9) 219 (64) 121 (36)
CBCS Carolina Breast Cancer Study 635 589 51 (12) 52 (11) 272 (46) 317 (54)
PLCO Prostate, Lungs, Colorectal and Ovarian
Cancer Screening Trial Cohort
56 116 68 (7) 68 (6) 14 (70) 6 (30)
NBHS Nashville Breast Health Study 304 182 54 (11) 52 (10) 143 (69) 65 (31)
WFBC Wake Forest University Breast Cancer Study 120 144 55 (12) 55 (11) 66 (61) 43 (39)
subtotal 3016 2745 55 (12) 58 (13) 1520 (61) 988 (39)
AMBER consortium
BWHS Black Women’s Health Study 752 2249 54 (10) 53 (11) 412(65) 218(35)
CBCS Carolina Breast Cancer Study 727 61 51 (11) 53 (9) 444(64) 252(36)
WCHS Women’s Circle of Health Study 505 629 54 (11) 51 (10) 237(70) 103(30)
subtotal 1984 2939 53 (11) 53 (10) 1093 (66) 573 (34)
Total 6657 7713 53 (12) 53 (13) 2987 (60) 1964 (40)
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development as molecularly targeted therapy for cancers (26).
Thus, TNFSF10 gene is a plausible causal gene in the region.
There appeared to be a second association signal in the
3q26.21/TNFSF10 region: rs9833271 was associated with ER-
negative breast cancer (A-allele, OR¼ 1.39, P¼ 3.7 10 5) and it
was in weak LD with the top signal SNP, rs13074711 (r2¼0.06).
After adjusting rs13074711, the association between rs9833271
and ER-negative breast cancer remained statistically significant
(p¼ 0.002) though the adjusted odds ratio was smaller (Table 3).
Interestingly, the risk allele of rs9833271 exists only in African
populations. Furthermore, a missense variant in exon 1 of
TNFSF10 (rs6763816, c.97G>A, Val33Ile) has a frequency of 0.04
in African populations, but is monomorphic in other popula-
tions; the minor allele of this missense variant was associated
Figure 1. Manhattan plots of –log10 of P-values in the meta-analysis of ROOT and AABC for overall, ERþ and ER- breast cancer risk.
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with reduced risk of ER-negative breast cancer (OR¼ 0.75;
P¼ 0.0012). Other SNPs that were in moderate LD with
rs13074711 were no longer statistically significant after adjust-
ing for rs13074711 (Table 3).
The expression quantitative trait locus (eQTL) analysis
showed that several significant SNPs in the 3q26.21/TNFSF10 re-
gion were associated with the expression of TNFSF10 in periph-
eral blood (27) or brain (28), but not in breast tumour (Table 4,
Supplementary Material, Fig. S3). We also examined the possibil-
ity that the breast cancer-associated SNPs influence TNFSF10 ex-
pression by serving as enhancer variants. The top associated
SNP, rs13074711, and its LD-linked SNPs were located in regions
of high histone H3 lysine 4 monomethylation (H3K4Me1) and his-
tone H3 lysine 27 acetylation (H3K27Ac) features that are charac-
teristic of enhancer elements (Fig. 2B). The second associated
SNP, rs9833271, was also located in an enhancer element.
Notably, strong enhancer features of these SNPs were found in
human mammary epithelial cells (HMEC) and breast myoepithe-
lial cells (MYO) (Table 4). The three SNPs close to the transcrip-
tional start site of TNFSF10 (rs6763816, rs16845798, and
rs17601879) also resided in transcription factor (GATA3) binding
sites in a ductal breast cancer cell line (T47D). The minor allele of
rs13074711 could alter multiple motifs. Taken together, these
lines of evidences suggest that the association between variants
in the 3q26.21 region and breast cancer risk may be mediated by
regulating TNFSF10 gene expression through enhancer activities.
The association signal around rs12998806 was confined to a
region of 87 Kb between 217.855 Mb and 217.942 Mb on chro-
mosome 2q35 (Supplementary Material, Fig S4). Variant
rs13387042 in this region has been associated with ER-positive
breast cancer in previous GWAS conducted mainly in popula-
tions of European ancestry (9,12). rs13387042 was associated
with breast cancer risk in some studies among African
Americans (29,30), but not in other studies among women of
African ancestry (9,31,32) or Asians (33). In the current study,
the A-allele of rs13387042 was significantly associated with ER-
positive breast cancer (OR¼ 1.16; P¼ 0.002), but the association
was weaker than with rs12998806. The two SNPs are in the
same LD block, separated by 12 Kb and correlated in both YRI
(r2¼0.63) and CEU (r2¼0.31) populations in the 1000 Genomes
Project. No gene was found in the LD block and the nearest
known genes include TNP1 (169 Kb), IGFBP5 (334 Kb) and IGFBP2
(365 Kb). One study proposed that rs4442975 (G-allele) regulation
of IGFBP5 gene expression is the underlying mechanism for
2q35 region’s effect on ER-positive breast cancer risk (33), but
rs4442975 was not associated with breast cancer risk in Asians
(33) and only weakly associated with breast cancer in our study
(OR¼ 1.12, P¼ 0.009). For the 2q35 locus, the LD pattern in
African populations is weaker than in European populations,
which may help to pinpoint the causal variants (Supplementary
Material, Fig. S5).
The rs10069690 SNP is located in intron 4 of the TERT gene
and the association signal was confined to a small region on
chromosome 5p15 (Supplementary Material, Fig. S6). The LD
pattern surrounding rs10069690 was weak in both African and
European populations, and few SNPs were correlated with
rs10069690 at r2>0.5 (Supplementary Material, Fig. S7). The
rs10069690 SNP was previously identified in a GWAS meta-
analysis of ER-negative breast cancer which included data from
the AABC consortium (21). The strength of association between
rs10069690 and ER-negative breast cancer in ROOT and AMBER
is very similar to that observed in AABC, suggesting that the T-
allele of rs10069690 is the best indicator of ER-negative breast
cancer at 5p15/TERT for women of African ancestry.T
ab
le
2.
A
ss
o
ci
at
io
n
be
tw
ee
n
th
re
e
lo
ci
an
d
br
ea
st
ca
n
ce
r
ri
sk
in
A
fr
ic
an
an
ce
st
ry
,b
y
ty
p
e
o
f
br
ea
st
ca
n
ce
r
C
yt
o
ba
n
d
,g
en
e
A
ll
el
es
(r
ef
er
en
ce
/
te
st
)
Im
p
u
ta
ti
o
n
sc
o
re
O
ve
ra
ll
br
ea
st
ca
n
ce
r
ER
-p
o
si
ti
ve
br
ea
st
ca
n
ce
r
ER
-n
eg
at
iv
e
br
ea
st
ca
n
ce
r
SN
P
Po
si
ti
o
n
*
St
u
d
y
R
A
F
O
R
(9
5%
C
I)
P
va
lu
e
O
R
(9
5%
C
I)
P
va
lu
e
O
R
(9
5%
C
I)
P
va
lu
e
2q
35
rs
12
99
88
06
21
78
93
76
3
A
/G
R
O
O
T
0.
99
5
0.
87
1.
09
(0
.9
5-
1.
26
)
0.
22
1.
21
(0
.9
5-
1.
54
)
0.
12
0.
88
(0
.7
0-
1.
12
)
0.
30
A
A
B
C
0.
99
2
0.
86
1.
20
(1
.0
8-
1.
34
)
0.
00
11
1.
45
(1
.2
6-
1.
67
)
3.
0E
-0
7
1.
00
(0
.8
6-
1.
16
)
0.
99
A
M
B
ER
T
yp
ed
0.
86
1.
14
(0
.9
9-
1.
31
)
0.
07
6
1.
24
(1
.0
3-
1.
49
)
0.
02
2
1.
07
(0
.8
5-
1.
34
)
0.
56
C
o
m
bi
n
ed
0.
86
1.
15
(1
.0
7-
1.
24
)
0.
00
01
7
1.
34
(1
.2
1-
1.
48
)
2.
2E
-0
8
0.
99
(0
.8
8-
1.
10
)
0.
84
P
fo
r
he
te
ro
ge
ne
it
y
0.
57
0.
27
0.
51
3q
26
.2
1
T
N
FS
F1
0
rs
13
07
47
11
17
22
67
80
3
C
/T
R
O
O
T
0.
98
7
0.
67
1.
03
(0
.9
3-
1.
14
)
0.
53
0.
86
(0
.7
3-
1.
02
)
0.
09
1.
11
(0
.9
3-
1.
33
)
0.
24
A
A
B
C
T
yp
ed
0.
70
1.
23
(1
.1
3-
1.
34
)
1.
9E
-0
6
1.
18
(1
.0
6-
1.
31
)
0.
00
17
1.
37
(1
.2
1-
1.
55
)
4.
1E
-0
7
A
M
B
ER
T
yp
ed
0.
69
1.
15
(1
.0
3-
1.
28
)
0.
01
5
1.
15
(1
.0
0-
1.
32
)
0.
04
9
1.
30
(1
.0
9-
1.
56
)
0.
00
38
C
o
m
bi
n
ed
0.
69
1.
14
(1
.0
8-
1.
21
)
2.
1E
-0
6
1.
10
(1
.0
2-
1.
19
)
0.
00
94
1.
29
(1
.1
8-
1.
40
)
1.
8E
-0
8
P
fo
r
he
te
ro
ge
ne
it
y
0.
04
0.
00
7
0.
16
5p
15
.3
3
T
ER
T
rs
10
06
96
90
12
79
79
0
C
/T
R
O
O
T
T
yp
ed
0.
63
1.
15
(1
.0
4-
1.
26
)
0.
00
49
1.
11
(0
.9
4-
1.
31
)
0.
21
1.
27
(1
.0
8-
1.
50
)
0.
00
48
A
A
B
C
T
yp
ed
0.
59
1.
13
(1
.0
4-
1.
22
)
0.
00
22
1.
08
(0
.9
8-
1.
19
)
0.
11
1.
31
(1
.1
7-
1.
47
)
2.
3E
-0
6
A
M
B
ER
T
yp
ed
0.
60
1.
11
(1
.0
0-
1.
23
)
0.
04
9
1.
06
(0
.9
3-
1.
20
)
0.
37
1.
31
(1
.1
1-
1.
54
)
0.
00
16
C
o
m
bi
n
ed
0.
60
1.
13
(1
.0
7-
1.
19
)
4.
8E
-0
6
1.
08
(1
.0
1-
1.
16
)
0.
03
1.
30
(1
.2
0-
1.
41
)
2.
4E
-1
0
P
fo
r
he
te
ro
ge
ne
it
y
0.
88
0.
91
0.
94
*N
C
B
IB
u
il
d
37
p
o
si
ti
o
n
.
A
bb
re
vi
at
io
n
:E
R
,o
es
tr
o
ge
n
re
ce
p
to
r;
O
R
,a
ll
el
ic
o
d
d
s
ra
ti
o
;C
I,
co
n
fi
d
en
ce
in
te
rv
al
;R
A
F,
ri
sk
(t
es
t)
al
le
le
fr
eq
u
en
cy
.
4839Human Molecular Genetics, 2016, Vol. 25, No. 21 |
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/25/21/4835/2525910 by U
niversity of N
orth C
arolina at C
hapel H
ill user on 14 August 2019
Discussion
In the largest breast cancer GWAS conducted in women of
African ancestry with more than 14,000 cases and controls, we
have identified 3q26.31 locus as a novel risk region for ER-
negative breast cancer. The second signal SNP and a missense
variant in 3q26.31 locus only exists in African ancestry popula-
tions, which may explain why this locus had not been detected
in previous GWAS of other populations. Functional annotation
of the associated variants suggests that the nearby TNFSF10
gene may be the causal gene underlying this association. We
also found and confirmed breast cancer risk variants that are
specific for African Americans at two known susceptibility re-
gions. These findings showed that genome-wide scans of com-
mon and rare genetic variants carried out in diverse
Figure 2. The 3q26.21/TNFSF10 locus tagged by rs13074711. (A) The regional Manhattan plot shows the –log10 P values for testing SNPs in 250kb region with ER- breast
cancer risk in the meta-analysis of the ROOT, AABC and AMBER studies. The colours depict the strength of the correlation (r2) between SNP rs13074711 and the SNPs
tested in the region. The correlation is estimated using the African panel of the 1000 Genomes Project data. The blue line indicates the recombination rates in centi-
morgans per megabase. (B) Analysis of regulation enhancer with data from ENCODE through UCSC Genome Browser, including histone modification marks for
H3K4Me1 and H3K27Ac of seven cell types, transcription factor binding sites and DNase hypersensitivity sites of human mammary epithelial cells (HMEC), breast can-
cer cells (MCF7, T-47D). Chromosomal coordinates are in NCBI build 37.
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populations can reveal additional susceptibility alleles for
breast cancer, and population-specific risk variants are impor-
tant for building appropriate risk prediction models.
Interestingly, the associations with the three breast cancer
risk susceptibility loci depend on ER status, which reinforces
the need for even larger discovery efforts for etiologically dis-
tinct breast cancer subtypes. The risk allele frequency for
rs10069690 in 5p15/TERT locus is greater in African populations
(0.62) than in European ancestry populations (0.27), and the risk
allele of rs9833271 exists only in African populations. These
may contribute to the higher proportion of ER-negative breast
cancer in women of African ancestry. By contrast, the risk allele
frequency for rs13074711 is smaller in African populations (0.61)
than in European ancestry populations (0.89), and the risk allele
frequency for rs12998806 is greater in African populations (0.78)
than in women of European ancestry (0.66), suggesting that
these two loci may not account for racial differences in subtype
distribution but more definitive studies are warranted.
The aetiology of ER-negative breast cancer is largely un-
known, and our study findings that the association for all three
top loci varies by ER status provide important insight into dis-
tinct biological pathways for ER-positive and ER-negative breast
cancers, which will benefit both breast cancer treatment and
prevention. In particular, theses data can be used to improve
risk prediction model for aggressive forms of breast cancer in di-
verse populations. We provide several lines of evidence that the
association at 3q26.31 region may be mediated by regulation of
TNFSF10 gene expression, and TNFSF10 is important for tumour
apoptosis. Further functional experiments will be needed to
confirm whether the TNFSF10 gene is a susceptibility gene for
ER-negative breast cancer and to fully understand how genetic
variants affect risk of breast cancer in diverse populations and
why the associations vary by breast cancer subtype.
Materials and Methods
Study populations
All the studies included in the GWAS have been approved by
their corresponding Institutional Review Boards. Informed con-
sent has been obtained from the participants. The discovery
stage (stage 1) of the study is a meta-analysis of genome-wide
association studies in two breast cancer consortia among
women of African ancestry. The ROOT (GWAS in Breast Cancer
in the African Diaspora) consortium consists of six epidemio-
logic studies and the AABC (African American Breast Cancer)
Table 3. Selected variants in 3q26/TNFSF10 region: their association with oestrogen-receptor negative breast cancer, and their linkage disequi-
librium with rs13074711 (the top SNP in the region)
Variant Position* Allele† r2 in YRI r2 in CEU Study RAF OR (95% CI) P value AOR (95% CI)‡ P value‡
rs6763816 Val33Ile C/T 0.08 NA ROOT 0.06 0.92 (0.66-1.28) 0.62 0.98 (0.68-1.39) 0.90
Exon 1 AABC 0.05 0.73 (0.56-0.94) 0.014 0.85 (0.65-1.11) 0.22
AMBER 0.06 0.60 (0.41-0.87) 0.0079 0.65 (0.44-0.98) 0.038
Combined 0.06 0.75 (0.62-0.89) 0.0012 0.83 (0.69-1.01) 0.058
rs16845798 13767 G/A 0.44 0.75 ROOT 0.73 1.03 (0.85-1.24) 0.79 0.88 (0.67-1.16) 0.37
AABC 0.74 1.25 (1.10-1.42) 6.7E-04 0.95 (0.78-1.15) 0.57
Combined 0.74 1.17 (1.06-1.30) 0.0031 0.92 (0.79-1.08) 0.33
rs17601879 16833 C/T 0.25 0.32 ROOT 0.81 1.00 (0.81-1.22) 0.98 0.87 (0.67-1.14) 0.32
AABC 0.81 1.24 (1.08-1.43) 0.0025 0.97 (0.80-1.16) 0.71
Combined 0.81 1.16 (1.03-1.30) 0.014 0.93 (0.80-1.09) 0.38
rs7650827 18258 C/T 0.36 0.32 ROOT 0.78 1.04 (0.85-1.27) 0.69 0.92 (0.70-1.22) 0.58
AABC 0.80 1.27 (1.10-1.46) 7.9E-04 0.98 (0.81-1.19) 0.86
Combined 0.79 1.19 (1.06-1.34) 0.0029 0.96 (0.82-1.13) 0.65
rs9809402 22074 C/T 0.25 0.09 ROOT 0.30 1.14 (0.96-1.35) 0.15 1.10 (0.92-1.33) 0.30
AABC 0.32 1.19 (1.06-1.34) 0.0031 1.05 (0.92-1.20) 0.43
Combined 0.31 1.17 (1.07-1.29) 0.0011 1.07 (0.96-1.19) 0.22
rs7627427 23005 G/C 0.25 0.09 ROOT 0.29 1.04 (0.87-1.25) 0.66 1.00 (0.83-1.21) 0.99
AABC 0.29 1.19 (1.05-1.35) 0.0053 1.07 (0.94-1.22) 0.29
Combined 0.29 1.14 (1.03-1.26) 0.011 1.05 (0.94-1.17) 0.38
rs9833915 24723 G/A 0.75 1.0 ROOT 0.60 1.06 (0.90-1.26) 0.47 0.93 (0.69-1.26) 0.64
AABC 0.61 1.26 (1.12-1.42) 8.1E-05 0.95 (0.77-1.15) 0.58
Combined 0.61 1.20 (1.09-1.32) 2.5E-04 0.94 (0.80-1.11) 0.47
rs13074711 26505 C/T 1.0 1.0 ROOT 0.67 1.11 (0.93-1.33) 0.24 NA NA
AABC 0.69 1.37 (1.21-1.55) 4.1E-07
AMBER 0.69 1.30 (1.09-1.56) 0.0038
Combined 0.69 1.29 (1.18-1.40) 1.8E-08
rs9833271 37244 G/A 0.06 NA ROOT 0.07 1.63 (1.19-2.24) 0.0024 1.59 (1.15-2.18) 0.0046
AABC 0.06 1.32 (1.06-1.64) 0.012 1.18 (0.94-1.47) 0.15
AMBER 0.06 1.32 (0.95-1.82) 0.095 1.23 (0.89-1.71) 0.21
Combined 0.06 1.39 (1.19-1.63) 3.7E-05 1.28 (1.09-1.50) 0.002
*base pair upstream of the transcription starting site of TNFSF10.
†reference allele/test allele.
‡conditional analysis adjusted for SNP rs13074711.
Abbreviation: NA, not applicable; OR, allelic odds ratio; CI, confidence interval; RAF, risk (test) allele frequency; YRI, Yoruba in Ibadan, Nigeria; CEU, Utah residents with
Northern and Western European ancestry.
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consortium consists of nine epidemiological studies (34). The
replication stage (stage 2) of the study is based on the AMBER
(African American Breast Cancer Epidemiology and Risk) con-
sortium, which consists of four epidemiologic studies (35).
Selected characteristics of study participants for each study are
summarized in Table 1. The study design for each study is de-
scribed in the Supplementary Materials.
Genome-wide genotyping and quality control
Genotyping in the ROOT consortium was conducted using the
Illumina HumanOmni2.5-8v1 array. Genotyping was attempted
for a total of 3,909 study samples, of which 3,859 were success-
ful. The 3,859 study samples were derived from 3,774 subjects,
with 85 subjects with duplicate samples. After genotyping, qual-
ity control analysis was carried out by checking chromosomal
anomalies, participant relativeness, population structure, miss-
ing call rates, batch effects, duplicate sample discordance,
Mendelian errors, Hardy-Weinberg equilibrium, and duplicate
SNP probes. First, duplicate samples from 85 pairs were ex-
cluded. Chromosomal anomalies>5 Mb and anomalies on chro-
mosomes where the sum of the anomaly lengths>10 Mb were
identified. No subjects were excluded for this reason but all ge-
notypes were set to missing for regions with chromosome
anomalies. The relatedness between each pair of participants
was evaluated by the identical by descent (IBD) analysis.
According to the IBD analysis, samples from 59 subjects were
excluded because they were possibly relatives of other subjects.
Additionally, 20 subjects (18 African Americans and 2 African
Barbadian) were excluded because principal components analy-
sis showed that they were clustered with the CEU/TSI HapMaps
(i.e. high percentage of European ancestry). We further filtered
out 7 samples with a missing call rate> 2% and 2 samples with
possible tumour contamination. After these exclusions, a total
of 3,686 subjects (1,657 cases and 2,029 controls) were included
for the final analysis.
A total of 2,379,855 SNP probes were attempted in Illumina
HumanOmni2.5-8v1 array. In the SNP level quality control analy-
sis, 32,192 SNPs with technical errors, 119,924 SNPs with minor
allele frequency¼ 0 and 5,631 duplicate SNPs were excluded. We
further filtered out 99,511 SNPs with missing call rate >¼ 2%, 563
SNPs with>1 discordant calls, 1,078 SNPs with>1 Mendelian er-
rors and 4,591 SNPs with Hardy-Weinberg equilibrium test
P< 10 4. After these exclusions, 2,116,365 SNP remained.
Genotyping in the AABC consortium was conducted using
the IlluminaHuman1M-Duo BeadChip. Of the 5,984 samples
available to the AABC consortium (3,153 cases and 2,831 con-
trols), we attempted genotyping of 5,932, removing samples
(n¼ 52) with DNA concentrations<20 ng/ul. Following genotyp-
ing, we removed samples based on the following exclusion cri-
teria: 1) unknown replicates (98.9% genetically identical) that
we were able to confirm (only one of each duplicate was re-
moved, n¼ 15); 2) unknown replicates that we were not able to
confirm through discussions with study investigators (pair or
triplicate removed, n¼ 14); 3) samples with call rates<95% after
a second attempt (n¼ 100); 4) samples with 5% African ances-
try (n¼ 36); and, 5) samples with<15% mean heterozygosity of
SNPs in the X chromosome and/or similar mean allele intensi-
ties of SNPs on the X and Y chromosomes (n¼ 6) (these are likely
to be males).
In the analysis, we removed SNPs with<95% call rate
(n¼ 21,732) or minor allele frequencies (MAFs)<1% (n¼ 80,193).
To assess genotyping reproducibility, we included 138 replicate
samples; the average concordance rate was 99.95% (>99.93% for
all pairs). We also eliminated SNPs with genotyping concor-
dance rates<98% based on the replicates (n¼ 11,701). The final
analysis dataset included 1,043,036 SNPs genotyped on 3,016
cases and 2,745 controls, with an average SNP call rate of 99.7%
and average sample call rate of 99.8%. Hardy-Weinberg equilib-
rium (HWE) was not used as a criterion for removing SNPs at
this stage.
Imputation and technical validation by sequencing
Genotype imputation for the ROOT consortium was conducted
by the University of Washington Genetics Coordinating Center
(GCC) using the IMPUTE2 software (23). Following filters for ge-
notype imputation, including no ambiguity in strand alignment
and ability to be mapped to NCDB build 37, 2,018,833 SNPs were
selected as the basis for imputation. Using the 1000 Genomes
Project phase I integrated variant set as the reference panel
(October 2011 release), 20,109,249 SNPs were imputed. Of these,
16,147,413 have passed the imputation quality filter (imputation
score>0.3) and were included along with the genotyped SNPs in
the final association analysis. Genotype imputation in AABC
was conducted using IMPUTE2 software (23) to a cosmopolitan
panel of all 1000 Genome Project subjects (March 2012 release).
To provide technical validation, we sequenced 96 samples
that have been included in the final analysis of the ROOT
GWAS. We conducted whole genome sequencing on the
Illumina platform, with average depth of 30x. The concordance
rate between whole genome sequencing and array-based geno-
typing was 99.5%.
Genotyping in the replication stage
Genotyping of the AMBER cases and controls was performed on
the Illumina Human Exome Beadchip v1.1 with additional cus-
tom content at the Center for Inherited Disease Research (CIDR).
The standard content of this array includes more than 240,000
coding variants, as well as ancestry informative markers (AIMs).
Twenty thousand variants identified in the AABC/ROOT meta-
analysis, including 2 or more variants per associated region for
the top 5000 loci, were included as part of the custom content.
Of 405,555 SNPs attempted for genotyping, 381,212 were re-
leased by CIDR and 299,873 of these remained after removing SNPs
that were monomorphic (n¼ 70,761), were positional duplicates,
were on the Y chromosome, had Hardy-Weinberg Equilibrium
(HWE) P< 10 4, had call rate< 0.98, had> 1 Mendelian errors in
trios from HapMap (http://hapmap.ncbi.nlm.nih.gov/), or had> 2
discordant calls in duplicate samples. IMPUTE2 was used to impute
additional variants using the 1000 Genomes Phase I reference
panel (5/21/2011 1000G data, December 2013 haplotype release in
IMPUTE2 site). For the meta-analysis, 18,376 SNPs passed quality
control and included in the study.
Statistical analysis
In the ROOT GWAS, we analysed genotyped SNPs and imputed
SNPs with imputation score>0.3 using SNPTEST software to ac-
count for uncertainty in imputation (36). We examined the asso-
ciation of each SNP and breast cancer risk using unconditional
logistic regression, adjusting for age, study site and the first four
eigenvectors from principal component analysis. The first four
eigenvectors were used to control for population stratification
as only the first 4 eigenvectors were associated with case status.
4843Human Molecular Genetics, 2016, Vol. 25, No. 21 |
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/25/21/4835/2525910 by U
niversity of N
orth C
arolina at C
hapel H
ill user on 14 August 2019
Odds ratios (OR) and 95% confidence intervals (CI) were calcu-
lated from the multivariable logistic regressions. All tests of sta-
tistical significance were two-sided. Using similar methods, we
conducted an analysis to compare ER-positive breast cancers
with controls and compare ER-negative breast cancers with
controls, in order to identify subtype-specific SNPs.
In the AABC GWAS, we analysed genotyped SNPs and im-
puted SNPs with imputation score>0.3 and minor allele fre-
quency>0.01. Unconditional logistic regression was used to
examine the association between each SNP and overall breast
cancer risk, ER-positive and ER-negative breast cancer risk sepa-
rately. Age, the first 10 eigenvectors from principal component
analysis, and study site were adjusted for in the logistic regres-
sion. To be conservative, all the first 10 eigenvectors were used
to control population stratification. The SFBCS and NC-BCFR
studies were conducted in the same San Francisco Bay Area
population and were combined as one study site in the
analyses.
In the replication study, principal components were com-
puted using the smartpca program in the EIGENSOFT package.
No eigenvectors from the principal component analysis were
strongly associated with case status after controlling for the
matching factors, DNA source and study. ORs and 95% CIs for
each SNP were estimated in the analyses adjusted for study,
age, geographic region, DNA source and eigenvectors 5, 6 and 8,
which were associated with cases status at P< 0.10. Regression
coefficients (log odds ratios) and their standard errors, from the
two GWAS and the replication study were combined using a
fixed effect meta-analysis method.
Functional annotation
For each top variant and region identified in this study, we used
HaploReg (37) and USCS Genome Browser to explore functional
annotations of noncoding variants. Chromatin states (pro-
moters and enhancers), conserved regions, variant effect on
regulatory motifs, and protein binding sites were assessed from
available data from the ENCODE (38) and the Roadmap
Epigenomics Consortium (39). Data from breast tumour cell
lines (MCF-7, T-47D) and normal mammary epithelial cells
(HMEC, MYO, vMHEC) were emphasized.
Data on expression quantitative trait locus (eQTL) analysis in
blood were obtained from Westra et al. (27), in which eQTLs were
identified in a meta-analysis in 5,311 peripheral untransformed
blood samples and replication analysis in another 2,775 samples
(27). Data on eQTL analysis in brain were obtained from 400
autopsied subjects (28). Analysis on eQTL in breast tumours was
conducted using 46 ERþbreast tumours and 45 ER- breast tu-
mours from The Cancer Genome Atlas (TCGA). Only samples
from African Americans were included. Copy number change
and methylation status were controlled for in the eQTL analysis
in tumours with MatrixEQTL package in Bioconductor.
Supplementary Material
Supplementary Material is available at HMG online.
Conflict of Interest statement. None declared.
Funding
The ROOT Consortium was supported by National Cancer
Institute grants R01-CA142996, P50-CA125183, R01-CA89085 and
U01-CA161032. DH and OIO were also supported by American
Cancer Society (MRSG-13-063-01-TBG and CRP-10-119-01-CCE).
AABC was supported by a Department of Defense Breast Cancer
Research Program Era of Hope Scholar Award to CAH
[W81XWH-08-1-0383] and the Norris Foundation. Each of the
participating AABC studies was supported by the following
grants: MEC (National Institutes of Health grants R01-CA63464
and R37-CA54281); CARE (National Institute for Child Health
and Development grant NO1-HD-3-3175, K05 CA136967); WCHS
(U.S. Army Medical Research and Material Command
(USAMRMC) grant DAMD-17-01-0-0334, the National Institutes
of Health grant R01-CA100598, and the Breast Cancer Research
Foundation; SFBCS (National Institutes of Health grant R01-
CA077305 and United States Army Medical Research Program
grant DAMD17-96-6071); NC-BCFR (National Institutes of Health
grant U01-CA069417); CBCS (National Institutes of Health
Specialized Program of Research Excellence in Breast Cancer,
grant number P50-CA58223 and Center for Environmental
Health and Susceptibility National Institute of Environmental
Health Sciences, National Institutes of Health, grant number
P30-ES10126); PLCO (Intramural Research Program, National
Cancer Institute, National Institutes of Health); NBHS (National
Institutes of Health grant R01-CA100374). The Breast Cancer
Family Registry (BCFR) was supported by the National Cancer
Institute, National Institutes of Health under RFA-CA-06-503
and through cooperative agreements with members of the
Breast Cancer Family Registry and Principal Investigators. The
content of this manuscript does not necessarily reflect
the views or policies of the National Cancer Institute or any of
the collaborating centres in the BCFR, nor does mention of trade
names, commercial products, or organizations imply endorse-
ment by the U.S. Government or the BCFR. AMBER was sup-
ported by the National Cancer Institute grants P01-CA151135,
R01-CA098663, R01-CA058420, UM1-CA164974, R01-CA100598,
UM1-CA164973, R01-CA54281, P50-CA58223, and the University
Cancer Research Fund of North Carolina. Pathology data were
obtained from numerous state cancer registries (Arizona,
California, Colorado, Connecticut, Delaware, District of
Columbia, Florida, Georgia, Hawaii, Illinois, Indiana, Kentucky,
Louisiana, Maryland, Massachusetts, Michigan, New Jersey,
New York, North Carolina, Oklahoma, Pennsylvania, South
Carolina, Tennessee, Texas, Virginia). The results reported do
not necessarily represent their views or the views of the
National Institutes of Health.
References
1. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J.
and Jemal, A. (2015) Global cancer statistics, 2012. CA. Cancer
J. Clin., 65, 87–108.
2. Carey, L.A., Perou, C.M., Livasy, C.A., Dressler, L.G., Cowan,
D., Conway, K., Karaca, G., Troester, M.A., Tse, C.K.,
Edmiston, S., et al. (2006) Race, breast cancer subtypes, and
survival in the Carolina Breast Cancer Study. JAMA, 295,
2492–2502.
3. Huo, D., Ikpatt, F., Khramtsov, A., Dangou, J.M., Nanda, R.,
Dignam, J., Zhang, B., Grushko, T., Zhang, C., Oluwasola, O.,
et al. (2009) Population differences in breast cancer: survey in
indigenous african women reveals over-representation of
triple-negative breast cancer. J. Clin. Oncol., 27, 4515–4521.
4. Eng, A., McCormack, V. and dos-Santos-Silva, I. (2014)
Receptor-defined subtypes of breast cancer in indigenous
populations in Africa: a systematic review and meta-analy-
sis. PLoS Med., 11, e1001720.
4844 | Human Molecular Genetics, 2016, Vol. 25, No. 21
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/25/21/4835/2525910 by U
niversity of N
orth C
arolina at C
hapel H
ill user on 14 August 2019
5. Michailidou, K., Hall, P., Gonzalez-Neira, A., Ghoussaini, M.,
Dennis, J., Milne, R.L., Schmidt, M.K., Chang-Claude, J.,
Bojesen, S.E., Bolla, M.K., et al. (2013) Large-scale genotyping
identifies 41 new loci associated with breast cancer risk. Nat.
Genet., 45, 353–361. 361e351-352.
6. Michailidou, K., Beesley, J., Lindstrom, S., Canisius, S.,
Dennis, J., Lush, M.J., Maranian, M.J., Bolla, M.K., Wang, Q.,
Shah, M., et al. (2015) Genome-wide association analysis of
more than 120,000 individuals identifies 15 new susceptibil-
ity loci for breast cancer. Nat. Genet., 47, 373–380.
7. Easton, D.F., Pooley, K.A., Dunning, A.M., Pharoah, P.D.,
Thompson, D., Ballinger, D.G., Struewing, J.P., Morrison, J.,
Field, H., Luben, R., et al. (2007) Genome-wide association
study identifies novel breast cancer susceptibility loci.
Nature, 447, 1087–1093.
8. Hunter, D.J., Kraft, P., Jacobs, K.B., Cox, D.G., Yeager, M.,
Hankinson, S.E., Wacholder, S., Wang, Z., Welch, R.,
Hutchinson, A., et al. (2007) A genome-wide association
study identifies alleles in FGFR2 associated with risk of spo-
radic postmenopausal breast cancer. Nat. Genet., 39, 870–874.
9. Stacey, S.N., Manolescu, A., Sulem, P., Rafnar, T.,
Gudmundsson, J., Gudjonsson, S.A., Masson, G.,
Jakobsdottir, M., Thorlacius, S., Helgason, A., et al. (2007)
Common variants on chromosomes 2q35 and 16q12 confer
susceptibility to estrogen receptor-positive breast cancer.
Nat. Genet., 39, 865–869.
10. Stacey, S.N., Manolescu, A., Sulem, P., Thorlacius, S.,
Gudjonsson, S.A., Jonsson, G.F., Jakobsdottir, M.,
Bergthorsson, J.T., Gudmundsson, J., Aben, K.K., et al. (2008)
Common variants on chromosome 5p12 confer susceptibil-
ity to estrogen receptor-positive breast cancer. Nat. Genet.,
40, 703–706.
11. Ahmed, S., Thomas, G., Ghoussaini, M., Healey, C.S.,
Humphreys, M.K., Platte, R., Morrison, J., Maranian, M.,
Pooley, K.A., Luben, R., et al. (2009) Newly discovered breast
cancer susceptibility loci on 3p24 and 17q23.2. Nat. Genet., 41,
585–590.
12. Zheng, W., Long, J., Gao, Y.T., Li, C., Zheng, Y., Xiang, Y.B.,
Wen, W., Levy, S., Deming, S.L., Haines, J.L., et al. (2009)
Genome-wide association study identifies a new breast can-
cer susceptibility locus at 6q25.1. Nat. Genet., 41, 324–328.
13. Thomas, G., Jacobs, K.B., Kraft, P., Yeager, M., Wacholder, S.,
Cox, D.G., Hankinson, S.E., Hutchinson, A., Wang, Z., Yu, K.,
et al. (2009) A multistage genome-wide association study in
breast cancer identifies two new risk alleles at 1p11.2 and
14q24.1 (RAD51L1). Nat. Genet., 41, 579–584.
14. Turnbull, C., Ahmed, S., Morrison, J., Pernet, D., Renwick, A.,
Maranian, M., Seal, S., Ghoussaini, M., Hines, S., Healey, C.S.,
et al. (2010) Genome-wide association study identifies five
new breast cancer susceptibility loci. Nat. Genet., 42, 504–507.
15. Antoniou, A.C., Wang, X., Fredericksen, Z.S., McGuffog, L.,
Tarrell, R., Sinilnikova, O.M., Healey, S., Morrison, J.,
Kartsonaki, C., Lesnick, T., et al. (2010) A locus on 19p13
modifies risk of breast cancer in BRCA1 mutation carriers
and is associated with hormone receptor-negative breast
cancer in the general population. Nat. Genet., 42, 885–892.
16. Fletcher, O., Johnson, N., Orr, N., Hosking, F.J., Gibson, L.J.,
Walker, K., Zelenika, D., Gut, I., Heath, S., Palles, C., et al.
(2011) Novel breast cancer susceptibility locus at 9q31.2: re-
sults of a genome-wide association study. J. Natl Cancer Inst.,
103, 425–435.
17. Ghoussaini, M., Fletcher, O., Michailidou, K., Turnbull, C.,
Schmidt, M.K., Dicks, E., Dennis, J., Wang, Q., Humphreys,
M.K., Luccarini, C., et al. (2012) Genome-wide association
analysis identifies three new breast cancer susceptibility
loci. Nat. Genet., 44, 312–318.
18. Siddiq, A., Couch, F.J., Chen, G.K., Lindstrom, S., Eccles, D.,
Millikan, R.C., Michailidou, K., Stram, D.O., Beckmann, L.,
Rhie, S.K., et al. (2012) A meta-analysis of genome-wide associ-
ation studies of breast cancer identifies two novel susceptibil-
ity loci at 6q14 and 20q11.Hum.Mol. Genet., 21, 5373–5384.
19. Garcia-Closas, M., Couch, F.J., Lindstrom, S., Michailidou, K.,
Schmidt, M.K., Brook, M.N., Orr, N., Rhie, S.K., Riboli, E.,
Feigelson, H.S., et al. (2013) Genome-wide association studies
identify four ER negative-specific breast cancer risk loci. Nat.
Genet., 45, 392–398. 398e391-392.
20. Bojesen, S.E., Pooley, K.A., Johnatty, S.E., Beesley, J.,
Michailidou, K., Tyrer, J.P., Edwards, S.L., Pickett, H.A., Shen,
H.C., Smart, C.E., et al. (2013) Multiple independent variants
at the TERT locus are associated with telomere length and
risks of breast and ovarian cancer. Nat. Genet., 45, 371–384.
384e371-372.
21. Haiman, C.A., Chen, G.K., Vachon, C.M., Canzian, F.,
Dunning, A., Millikan, R.C., Wang, X., Ademuyiwa, F.,
Ahmed, S., Ambrosone, C.B., et al. (2011) A common variant
at the TERT-CLPTM1L locus is associated with estrogen
receptor-negative breast cancer. Nat. Genet., 43, 1210–1214.
22. Howie, B.N., Donnelly, P. and Marchini, J. (2009) A flexible
and accurate genotype imputation method for the next gen-
eration of genome-wide association studies. PLoS Genetics, 5,
e1000529.
23. Wiley, S.R., Schooley, K., Smolak, P.J., Din, W.S., Huang, C.P.,
Nicholl, J.K., Sutherland, G.R., Smith, T.D., Rauch, C., Smith,
C.A., et al. (1995) Identification and characterization of a new
member of the TNF family that induces apoptosis. Immunity,
3, 673–682.
24. Consortium, G.T. (2015) Human genomics. The Genotype-
Tissue Expression (GTEx) pilot analysis: multitissue gene
regulation in humans. Science, 348, 648–660.
25. Rahman, M., Davis, S.R., Pumphrey, J.G., Bao, J., Nau, M.M.,
Meltzer, P.S. and Lipkowitz, S. (2009) TRAIL induces apopto-
sis in triple-negative breast cancer cells with a mesenchy-
mal phenotype. Breast Cancer Res. Treat., 113, 217–230.
26. Lemke, J., von Karstedt, S., Zinngrebe, J. and Walczak, H.
(2014) Getting TRAIL back on track for cancer therapy. Cell
Death Differ., 21, 1350–1364.
27. Westra, H.J., Peters, M.J., Esko, T., Yaghootkar, H.,
Schurmann, C., Kettunen, J., Christiansen, M.W., Fairfax,
B.P., Schramm, K., Powell, J.E., et al. (2013) Systematic identi-
fication of trans eQTLs as putative drivers of known disease
associations. Nat. Genet., 45, 1238–1243.
28. Zou, F., Chai, H.S., Younkin, C.S., Allen, M., Crook, J.,
Pankratz, V.S., Carrasquillo, M.M., Rowley, C.N., Nair, A.A.,
Middha, S., et al. (2012) Brain expression genome-wide asso-
ciation study (eGWAS) identifies human disease-associated
variants. PLoS Genetics, 8, e1002707.
29. Chen, F., Chen, G.K., Millikan, R.C., John, E.M., Ambrosone,
C.B., Bernstein, L., Zheng, W., Hu, J.J., Ziegler, R.G., Deming,
S.L., et al. (2011) Fine-mapping of breast cancer susceptibility
loci characterizes genetic risk in African Americans. Hum.
Mol. Genet., 20, 4491–4503.
30. Zheng, W., Cai, Q., Signorello, L.B., Long, J., Hargreaves, M.K.,
Deming, S.L., Li, G., Li, C., Cui, Y. and Blot, W.J. (2009)
Evaluation of 11 breast cancer susceptibility loci in African-
American women. Cancer. Epidemiol. Biomarkers Prev., 18,
2761–2764.
31. Huo, D., Zheng, Y., Ogundiran, T.O., Adebamowo, C.,
Nathanson, K.L., Domchek, S.M., Rebbeck, T.R., Simon, M.S.,
4845Human Molecular Genetics, 2016, Vol. 25, No. 21 |
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/25/21/4835/2525910 by U
niversity of N
orth C
arolina at C
hapel H
ill user on 14 August 2019
John, E.M., Hennis, A., et al. (2012) Evaluation of 19 suscepti-
bility loci of breast cancer in women of African ancestry.
Carcinogenesis, 33, 835–840.
32. Palmer, J.R., Ruiz-Narvaez, E.A., Rotimi, C.N., Cupples, L.A.,
Cozier, Y.C., Adams-Campbell, L.L. and Rosenberg, L. (2013)
Genetic susceptibility loci for subtypes of breast cancer in an
African American population. Cancer. Epidemiol. Biomarkers
Prev., 22, 127–134.
33. Ghoussaini, M., Edwards, S.L., Michailidou, K., Nord, S.,
Cowper-Sal Lari, R., Desai, K., Kar, S., Hillman, K.M.,
Kaufmann, S., Glubb, D.M., et al. (2014) Evidence that breast
cancer risk at the 2q35 locus is mediated through IGFBP5 reg-
ulation. Nat. Commun., 4, 4999.
34. Chen, F., Chen, G.K., Stram, D.O., Millikan, R.C., Ambrosone,
C.B., John, E.M., Bernstein, L., Zheng, W., Palmer, J.R., Hu, J.J.,
et al. (2013) A genome-wide association study of breast can-
cer in women of African ancestry. Hum. Genet., 132, 39–48.
35. Palmer, J.R., Ambrosone, C.B. and Olshan, A.F. (2014) A col-
laborative study of the etiology of breast cancer subtypes in
African American women: the AMBER consortium. Cancer
Causes Control, 25, 309–319.
36. Marchini, J. and Howie, B. (2010) Genotype imputation for
genome-wide association studies. Nat. Rev., 11, 499–511.
37. Ward, L.D. and Kellis, M. (2012) HaploReg: a resource for ex-
ploring chromatin states, conservation, and regulatory motif
alterations within sets of genetically linked variants. Nucleic
Acids Res., 40, D930–D934.
38. Encode Project Consortium (2011) A user’s guide to the ency-
clopedia of DNA elements (ENCODE). PLoS Biol., 9, e1001046.
39. Roadmap Epigenomics, C., Kundaje, A., Meuleman, W.,
Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A.,
Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) Integrative
analysis of 111 reference human epigenomes. Nature, 518,
317–330.
4846 | Human Molecular Genetics, 2016, Vol. 25, No. 21
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/25/21/4835/2525910 by U
niversity of N
orth C
arolina at C
hapel H
ill user on 14 August 2019
